jimmy Turano

Chelsea Therapeutics: There Are Safer Rebound Plays

VFC-While your writing articles, and still haven't replied to my posts
regarding 'MRNA', I thought you would like to see my posting of opinion, that was selected and published today, by "MEDICAL NEWS ADMINISTRATION". SOMEONE THINKS IT IS NEWS WORTHY TO POST ON THEIR FRONT PAGE.
www.medicalnewstoday.c...
THOUGHT SOMEONE LIKE YOU WITH YOUR STATURE WOULD TACKLE A CHALLENGE WITH EASE, INSTEAD OF THE SAME OLD WEEKLY EASY ARTICLES YOU WRITE ABOUT.
VFC-GIVES AN IN DEPTH STUDY & OPINION ON 'MRNA'

Four Biotech Stocks to Play the Sector Pullback

VFC-I am surprised you didn't include CELEGENE.
I AM NOT SURPRISED THAT YOU LEFT OUT 'MRNA'.
Which I have been requesting you to elaborate on for
the weary shareholders.
But VFC I think after this years turmoil on the stock market, economy, and many getting burnt financially already, it maybe time
for you to take a vacation. Regenerate, physically & mentally and
come back in January 2010 with a new attitude on investing.
Starting with you wearing a pinstripe suit,blue shirt, and red tie,
but sitting behind an oak desk, looking like a successful adviser
to the general public.
TIME TO WAKE UP VFC!

Stock Watch: BDSI, ACTC.PK, ONTY

As usual a very good report, your article is appreciated.
VFC, I OFFER YOU A CHALLENGE, SINCE YOU ARE FORTUNATE TO HAVE A JOB, AND AND YOU LOOK PRETTY HEALTHY IN YOUR PHOTO. YOUR BACKGROUND & KNOWLEDGE, AS A WRITER FOR SEEKINGALPHA IS JUST
PERFECT FOR YOU TO ACCEPT, AND LET ALL INVESTORS KNOW YOUR PERSPECTIVE ON 'MDRNA INC' (MRNA).
THERE ISN'T ONE REPUTABLE, KNOWLEDGEABLE WRITER,
ON THE ENTIRE INTERNET WILLING TO WRITE A BRIEF
ARTICLE ON 'MRNA'. INVESTORS NEED TO HEAR A NEUTRAL OPINION, INSTEAD OF THE RESEARCH FIRMS WHO FOLLOW IT, GIVE CHRONIC 'BUY' SIGNALS, AND RIDICULOUS HIGH TARGET PRICES.
AS A FORMER VIET NAM VETERAN, I AM ASKING YOU VFC
TO TELL IT LIKE IT REALLY IS ON "MRNA".
THANK YOU!

Taking Advantage of the BioDelivery Dip

Like BDSI on dip like you say, but with two looming forces approaching, this time I would wait, for sure.
One, is a Market correction, as sure as you are laying back in your photo.
Two, one of the terrorist attacks may get through in the coming weeks.
Either scenario, should be a big warning for investors to be prepared, and ahead of the curve.
09/27/09 If I am right, 10% further discount is on the way!

Short Interest in BioDelivery Sciences Is Good News

little frog I love bdsi for past 3 years.
I am sure it will turn out good for shareholders because they do have a FDA approved drug and good pipeline. But it is night and day difference from 'MRNA'. There is way to much Hype on the stock, with no phase1,2,3,4 drugs and decelerating assets and no serious Revenue too.
I just need someone like VFC to spell it out and give some feedback on this company the way it really is!


On Sep 02 12:50 PM littlefrog wrote:

> Jimmy you are missing one important point, MRNA doesn't have a FDA
> approved drug, BDSI does. there is a future revenue inflow right
> there for BDSI.
> But something does scare people away is the lack of clarity for BDSI's
> cost structure, i.e, how much profit will left after BDSI pays all
> expenses of drug manufacturing, and how well the drug will do in
> sales. the CFO was very vague about this in the CC.
>
> I agree with VFC that this stock is a long term play, more news is
> coming in Q4 when Onsolis starts selling, and another Phase II result
> for their pipeline. If Meda does a good job promoting Onsolis and
> the forementioned cost issue becomes clear, we are up to a very happy
> Christmas...
>
>

Short Interest in BioDelivery Sciences Is Good News

Terrific article! Now you may be the writer/expert to set things straight on 'MRNA'. My beef is simple. Since 2007, so many analysts,researchers, who follow this stock always release a buy signal and high target prices that are absolutely absurd. Since they follow the stock and have possibly obligations to put out positive
news, for whatever reasons, I find it totally misleading investors.
As you can confirm, the stock has gone from $20.00 to $.28 cents
during this time period. This year it has rebounded to $3.00 due to two new partnerships, but has settled back to around $1.42 the last two months. Recently, just 4 weeks ago, once again another analyst put a $4.00 target price. Now four weeks later the stock is around $1.35 cents. These people should be investigated period.
So now, what is your input on this matter, and the real future
prospect of this company?
Thank you in advance.
Jimmy T

Biggest Health Care Winners Become Biggest Losers After Friday's Market Action

MR.GARZA,
Please give your perspective on 'MRNA'
As I predicted when the stock was $10.21, ON THE MOTELY FOOL CAPS SITE, and the fact that the stock then hit $.14 cents,
two years later, speaks louder than words.
HOWS THAT FOR FORECASTING, MR.GARZA?
So this year 'MRNA' rallied to $1.99 on news of two partnerships, nd pure hype, creating an overbought, overpriced stock, that has now retreated to $1.42. I still believe
it is overpriced at this level and the trend is now bearish.
The only sad part for me, was that everyone at the SEC overlooked the fact that during all of 2007, the insiders were selling the most shares ever. And as we all know today, at the end of 2007, P&G broke up their partnership with then NSTK.
Does anyone believe that that was purely a coincidence by insiders? The SEC is to be shareholders advocates, but with all the corruption that unfolded since September 08 to present, it appears that the SEC
looked the other way.
CARE TO STEP UP TO THE PLATE MR.GARZA AND BE HEARD?

Stock Watch: Biodelivery Sciences Has Nearly Tripled Over Past Months

VFC-QUITE THE ASTUTE INVESTOR. MANY SHOULD LEARN FROM YOU INSTEAD OF HANGING ON TO A STOCK LIKE CRUCHES.
Your analogy above is and was a wake up call for 'MRNA' investors. Who similarly had a recent 650% move up to $1.99 on May19th, but today
15 days later its around $1.40.
But they have no FDA approval pending, and are in pre-clinical stages as a company.
There only premise is to find partners for their RNAI platform, which could be 5-8 years away from perfecting. Am I right VFC, that investors
ought not to be wasting their time with this company, MDRNA INC(MRNA)?

Bio-Pharma, Diagnostics Buyout Binge Begins

I don't see MDRNA INC(MRNA) on your list!
Or is it that it's cheaper for a group to enter a partnership with MRNA with all their RNAI potentials?
At $.36 cents right now and even further stock price decline because of year end earnings report, doesn't this pose an opportunity for PARTNER out there to fork up $30 million to keep this company from running out of money soon with so much potential?
Mike what's your perspective?